How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    • Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about nivolumab with ipilimumab

Marketing authorisation indication

2.1 Nivolumab (Opdivo, Bristol Myers Squibb) plus ipilimumab (Yervoy, Bristol Myers Squibb) has a marketing authorisation 'for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma'.

Dosage in the marketing authorisation

2.2 Both nivolumab and ipilimumab are administered intravenously. The recommended dose is 360 mg over 30 minutes every 3 weeks for nivolumab and 1 mg per kilogram over 30 minutes every 6 weeks for ipilimumab. Treatment is continued for up to 24 months or until disease progresses. More details are available in nivolumab's summary of product characteristics.

Price

2.3 The list price of nivolumab is £2,633 per 240 mg per 24‑ml vial (excluding VAT; BNF online, accessed August 2021). The list price of ipilimumab is £15,000 per 200 mg per 40‑ml vial (excluding VAT; BNF online, accessed August 2021). The company has commercial arrangements for nivolumab and ipilimumab (simple discount patient access schemes). These make nivolumab and ipilimumab available to the NHS with discounts and would have also applied to this indication if the technology had been recommended. The size of the discounts is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discounts.